PMFA
SABS icon

Plante Moran Financial Advisors’s SAB Biotherapeutics SABS Stock Holding History

Plante Moran Financial Advisors’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.1K Hold
5,925
– – ﹤0.01% 454
2026
Q1 		$22.7K Buy
+5,925
New +$23.6K ﹤0.01% 413

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Plante Moran Financial Advisors's SABS Position: Q2 2026 in Review

Plante Moran Financial Advisors held its SAB Biotherapeutics (SABS) position steady in Q2 2026 at 5,925 shares worth $23.1K. The position accounts for ﹤0.01% of the portfolio, ranked #454.

Plante Moran Financial Advisors first reported a position in SABS in Q1 2026 and has held it in 2 quarters since. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Plante Moran Financial Advisors held 5,925 shares of SAB Biotherapeutics worth $23.1K as of Q2 2026.
  • Plante Moran Financial Advisors left its SAB Biotherapeutics share count unchanged in Q2 2026.
  • SAB Biotherapeutics made up ﹤0.01% of Plante Moran Financial Advisors's portfolio in Q2 2026, its #454 holding.
  • Plante Moran Financial Advisors first reported a position in SAB Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Plante Moran Financial Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.